T Cells In Tumor Immunotherapy Articles & Analysis
27 news found
Phase 2 study completed enrollment ahead of schedule Posoleucel well-tolerated with no cases of graft rejection observed to date Overall decline in median BK viral load among patients completing 12 weeks of dosing with posoleucel or placebo (2:1 randomization) Posoleucel detected up to 12 weeks after last infusion Topline, unblinded study results from all 61 patients expected to be released ...
ByKalaris
Initiated posoleucel registrational study to prevent six devastating viral infections and now enrolling high-risk allo-HCT patients in the U.S., Western Europe and Asia FDA granted RMAT designation to posoleucel for Phase 3 multi-virus prevention indication with an estimated annual addressable patient population of 40,000 allo-HCT patients Progressed enrollment in three Phase 3 studies for ...
ByKalaris
AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead investigational multi-virus-specific T cell therapy, posoleucel, for the prevention of clinically significant infections and disease from six devastating viruses ...
ByKalaris
AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello brings more than 35 years of broad experience building and leading commercial organizations in the life sciences industry, with specific expertise in cell and gene therapy. “We’re thrilled to welcome Shawn ...
ByKalaris
Updated, preliminary Phase 2 data presented at EBMT Annual Meeting continue to demonstrate substantial reduction in the expected rate of clinically significant infections with posoleucel therapy 21 of 24 patients were free of clinically significant infections through the Week 14 primary endpoint AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today ...
ByKalaris
About VAXIMM VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s plug and play DNA vaccination technology is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic ...
AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:00 a.m. EST. A live webcast of the fireside chat will be available on the Investors & Press section of the AlloVir ...
ByKalaris
Three ongoing Phase 3 registrational studies of posoleucel expected in 2022, targeting treatment and prevention indications with no approved therapies Expanded enrollment in Phase 2 proof-of-concept study of posoleucel for the preemptive treatment of BK viremia in kidney transplant recipients; initial data submitted for presentation in 1H 2022 Advancing two additional virus-specific T cell ...
ByKalaris
Bristol-Myers Squibb K.K. today announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an ...
Treatment of AdV infection is posoleucel’s second potential indication to receive RMAT designation Phase 3 registrational study of posoleucel for AdV treatment is now open for enrollment Proof-of-concept study of ALVR106 for the treatment of multiple respiratory viral infections is also open for enrollment AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today ...
ByKalaris
AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 4:30 p.m. ET. An audio-only webcast of the presentation will be available on the Investors & Press section of the AlloVir website at. An ...
ByKalaris
(NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb (NYSE: BMY), today announced that they have entered into a license, development and commercialization agreement (the “agreement”) for ...
Complementary technology platforms, expertise and capabilities provide unique synergistic opportunities. Exciting product candidates for oncology and autoimmunity based on the innovative SNAPvaxTM platform, which has demonstrated unprecedented control over T cell induction. World-class scientific team out of the NIH’s Vaccine Research Center with deep R&D capabilities. U.S. ...
No dose limiting toxicities (DLTs) were observed since the previous data release on March 17, 2021. The data also revealed high T cell engraftment and persistence along with clinical responses which were associated with tumor infiltration. ...
(NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced an interim clinical data update from its TCR-engineered cell therapy (TCR-T) approach ACTengine® IMA203 targeting PRAME. ...
Indee Labs is a biotechnology company developing the µVS Delivery SystemTM for non-viral intracellular or gene delivery. The team at Indee Labs was awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop the µVS Delivery SystemTM for modified regulatory T cells. ...
Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care Three patients had complete responses, with another patient still under evaluation Tel Aviv, ...
(NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported its financial results for the quarter ended June 30, 2021 and provided a business update on its progress over the reporting period. ...
(NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported financial results and provided a business update for the quarter ended March 31, 2021. ...
Thermo Fisher Scientific Inc. has made a donation to the Leukemia & Lymphoma Society in recognition of the recent U.S. Food and Drug Administration approval of the first CAR T cell immunotherapy for multiple myeloma developed by Bristol Myers Squibb and bluebird bio. Abecma® (idecabtagene vicleucel; ide-cel) is a chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of ...